Food and Drug Administration approved Foundayo (orforglipron), an oral once-daily pill in the GLP-1 class and the first of its kind that can be taken at any time of
NAD+ levels decline by roughly 50% every 20 years, and this depletion is both a consequence and a driver of aging
This call to action builds on a recent joint position statement signed by the participating fitness industry groups, the World Obesity Federation (WOF), and the World Federation of the Sporting Goods Industry (WFSGI), which emphasized the urgency of ensuring physical activity and nutrition are central to systems supporting the global roll-out of obesity medications
Conserved class B GPCR activation by a biased intracellular agonist
Schedule your appointment today and take a proactive step toward recovery
Possesses knowledge of facial anatomy and facial contouring, and is well-versed in procedures such as thread lifts and hyaluronic acid injections